News | October 16, 2014

VeriTeQ License Multiple Radiation Dose Tracking Patents From NC State University

VeriTeQ NC State University Agreement Q Inside SmartMarker OneDose Dosimetry

October 16, 2014 — VeriTeQ Corp. announced it has entered an agreement providing an exclusive license of multiple patents from North Carolina State University (NCSU). VeriTeQ will license 24 patents, which are the foundation for its U.S. Food and Drug Administration (FDA)-cleared Q Inside SmartMarker and OneDose products for radiation dosimetry.

Q Inside SmartMarker (formerly known as DVS SmartMarker) is an implantable radiation sensor for use in breast and prostate cancer patients undergoing photon external beam treatments. It is implanted in, or adjacent to, solid-mass tumors and gathers data on the actual dose of radiation being delivered to the tumor and surrounding normal tissue. Q Inside SmartMarker is intended to be used in the balancing between delivering maximum dose to the tumor while minimizing the impact to healthy tissue. The sensor can confirm the treatment is conforming to the physician's plan, as even a small deviation from the planned dose can have a significant impact on patient survival rates.

VeriTeQ's OneDose external radiation sensing system is FDA cleared for use in patients being treated with external beam radiation. OneDose is a proprietary, wearable, single-use system that is used to verify radiation oncology doses quickly and conveniently. The OneDose system is comprised of disposable sensors that attach to the patient's skin using a basic adhesive and a scanner that reads the sensor. VeriTeQ believes OneDose is the only wireless, pre-calibrated, disposable, skin surface sensor that provides instant dose delivery data, which could be fed into patient radiology reports and health records.

"Expanding our relationship with NCSU not only helps strengthen our intellectual property portfolio, but, we believe, also better positions us to commercialize these important radiation measurement products through the benefit of a direct relationship with the source of the core science," said Scott R. Silverman, VeriTeQ's chairman and CEO. "Our team is highly focused on returning to market Q Inside SmartMarker and One Dose, which were previously used in numerous hospitals in the U.S. to help prevent radiation overdose."

The patents in questions were previously being made available to VeriTeQ through a sublicense agreement. The new, direct agreement with NCSU is effective immediately.

For more information: www.veriteqcorp.com

Related Content

Mevion Receives 510(k) Clearance for Hyperscan Pencil Beam Scanning Proton Therapy
Technology | Proton Therapy | January 04, 2018
Mevion Medical Systems has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the Mevion S250i...
Study Compares Radiosurgery and Whole-Brain Radiation in Lung Cancer Patients With Multiple Brain Metastases
News | Radiation Therapy | January 03, 2018
Although targeted therapies have produced dramatic advances in the ability to control some types of advanced lung...
MEDraysintell Downgrades Proton Therapy Market Projection for 2030
News | Proton Therapy | January 02, 2018
MEDraysintell recently downgraded its projection for proton therapy rooms expected to be operational in 2030 from 1,200...
California US Oncology Network Centers Adopt Xoft Electronic Brachytherapy System for Early-Stage Non-Melanoma Skin Cancer
News | Brachytherapy Systems | January 02, 2018
iCAD Inc. announced that its Xoft Axxent Electronic Brachytherapy (eBx) System is now available at two California-based...
Blue Phantom System Used for Acceptance of First European Varian Halcyon Machine
News | Radiation Therapy | January 02, 2018
IBA (Ion Beam Applications S.A.) announced in November the acceptance and beam model validation of the first Varian...
Study Finds Link Between Breast Cancer Treatments and Cellular Aging Markers
News | Women's Health | January 02, 2018
January 2, 2018 — A new study found women who had received chemotherapy and/or...
ACR Appropriateness Criteria Adds and Revises Topics for December 2017
News | Clinical Decision Support | December 29, 2017
December 29, 2017 — Radiologists can enhance the quality and effectiveness of care with the newest release of the ACR
FDA Clears GammaPod Stereotactic Radiotherapy System for Breast Cancer Treatment
Technology | Stereotactic Body Radiation Therapy (SBRT) | December 22, 2017
The U.S. Food and Drug Administration (FDA) has cleared the new GammaPod noninvasive stereotactic radiotherapy system...
RaySearch Launches RayCare Oncology Information System

Image courtesy of RaySearch Laboratories

Technology | Oncology Information Management Systems (OIMS) | December 22, 2017
RaySearch announced the first release of RayCare, a new oncology information system (OIS) designed to connect the...
RaySearch Releases RayStation 7 Radiotherapy Treatment Planning System
Technology | Treatment Planning | December 19, 2017
RayStation 7, the latest release of RaySearch’s radiation therapy treatment planning system, adds new functionality and...
Overlay Init